Introduction
Fabry disease is an X-linked inborn error of gylcosphingolipid catabolism resulting from the deficient activity of the lysosomal exoglycohydrolase, a-galactosidase A (EC 3.2.1.22; a-Gal A) (1) . Affected individuals accumulate neutral glycosphingolipids with termninal a-linked galactosyl moieties particularly in the plasma and in lysosomes of blood vessels, heart, liver, and kidney. In dassically affected males who have markedly deficient a-Gal A activity, the onset of the disease manifestations occurs in childhood or adolescence and is characterized by severe acroparesthesias, angiokeratoma, corneal opacities, and hypohydrosis. With advancing age, vascular disease of the heart, kidneys, and brain lead to early demise in adulthood. Asymptomatic or clinically milder hemizygotes with residual a-Gal A activity have an attenuated form of the disease limited to cardiac involvement (2) . The disease has a panethnic distribution with an estimated frequency of 1 in -40,000 males. The full-length a-Gal A cDNA encodes a polypeptide of 429 residues, induding a 31-amino acid signal peptide (3) . The -12 kb a-Gal A gene, located at Xq22.1 (Genome Database; www.gdb.org), contains seven exons, and the entire gene has been sequenced (4 For mutation analysis, genomic DNA was isolated from whole blood by standard techniques (11) . The entire coding region, including all exons and flanking intronic regions, was amplified by polymerase chain reaction (PCR) from genomic DNA in four fragments as previously described (9) and each amplified genomic region was sequenced using an ABI Prism 377 DNA Sequencer (Perkin-Elmer-Cetus, Norwalk, CT). Detected mutations were resequenced in genomic DNA from the proband and/or other affected family members.
To determine if the probands with mutation N215S were related, an intragenic marker, Sac I, and closely linked markers to the a-Gal A gene were examined. The markers were proximal flanking marker DXS7424 and the distal flanking markers DXS178, Al 1080, E03167, G0287, and DXS101 (12, 13) . These markers span a 4-cM region between Xq22.1 and Xq22.3 ( Fig. 1 ). All amplification reactions were carried out as previously described (12, 13) .
Results
The a-Gal A mutations causing Fabry disease in 30 unrelated probands were determined by mul- I I tiplex PCR amplification and automated sequencing of the entire coding sequence and adjacent intronic regions. No large a-Gal A rearrangements (>50 bp) were observed in any of the probands following electrophoresis of the PCR products. Sequencing revealed 20 novel mutations, each in an unrelated family, including 12 coding-region missense or nonsense mutations, 3 splice site defects, 1 single-base insertion, and 4 small deletions. In addition, 9 previously published mutations were identified in 10 families, including 5 missense (M42V, R112C, S 148R, D 165V, and N215 S), 3 nonsense (Q99X, C142X, and R227X), and 1 small deletion (1072del3). In each proband, sequencing the entire coding and adjacent flanking intronic regions revealed only a single lesion in each mutant allele. Table 1 summarizes the 20 novel and 9 recurrent mutations, the plasma a-Gal A activity, and the phenotype of the unrelated patients.
Of the 12 novel a-Gal A coding-region point mutations, all but one (P259L) were detected in classically affected probands, including 10 missense and 2 nonsense mutations. The missense mutations included the following: (1) a T-to-C transition of genomic nt g7323 in codon 142, resulting in a replacement of cysteine with arginine (C142R); (2) a G-to-A transition of genomic nt 8321 in codon 183, resulting in a substitution of aspartic acid for glycine (G183D); (3) a C-to-G transversion of genomic nt glO195 in codon 235, resulting in a serine-to-cysteine change (S235C); (4) a G-to-T transversion of genomic nt glO198 in codon 236, predicting a leucine-for-tryptophan substitution (W236L); (5) a G-to-C transversion of genomic nt g1O221 in codon 244, resulting in a replacement of aspartic acid with histidine (D244H); (6) a C-to-T transition of genomic nt g10267 in codon 259, predicting a proline-to-leucine change (P259L); (7) a G-to-A transition of genomic nt g10292 in codon 267, resulting in a substitution of methionine with isoleucine (M267I); (8) an A-to-T transversion of genomic nt 10573 in codon 289, resulting in an isoleucine-to-phenylalanine change (I289F); (9) a C-to-G transversion of genomic nt g10669 in codon 321, predicting a replacement of glutamine with glutamic acid (Q321E); and (10) a G-to-A transition of genomic nt gIl 111 in codon 378, resulting in a substitution of cysteine with tyrosine (C378Y). In addition, two novel nonsense mutations were detected, including a Cto-A transversion of genomic nt gi335 in codon 52 predicting a cysteine to termination codon (C52X) and a G-to-A transition of genomic nt g1O538 in codon 277, resulting in a tryptophan to termination codon (W277X).
Haplotype analysis of genomic DNAs from the two cardiac variant patients with the N215S mutation was performed with intragenic and flanking polymorphic markers (12, 13) . Although the patients' DNAs were uninformative for the Sac I intragenic marker (12) , their haplotypes differed at three markers, including two closely flanking markers ( Fig. 1 and Table 2 ).
Three novel splice site mutations were detected in three classically affected males. These included a single-base alteration at the 5' donor consensus splice site of intron 4 (designated IVS4+4; c639 + 4A --T), a single-base alteration at the 5' donor consensus splice site of intron 6 (designated IVS6+2; c999 + 2T -> C), and a single-base alteration at the 3' acceptor consensus site of intron 6 (designated IVS6-1; clOOO -1 G -> A). Each of these lesions is predicted to cause aberrant mRNA processing and exon skipping.
Five novel small gene rearrangements causing frameshift mutations were identified, each in a classically affected proband. These include the following: (1) an insertion of a T (892insT) after genomic nt g10600 that created a TGA termination signal in codon 299 and immediate termination of the polypeptide chain; (2) a 13-base deletion (35dell3) of genomic nt g1214-1249, which predicted a frameshift at codon 12 and incorporation of 105 different amino acids from residue 11 and then premature termination after residue 116; (3) a single-base deletion (256delT) of genomic nt g5155 that caused a frameshift in codon 86 and predicted the incorporation of 34 different amino acids and resulted in premature termination after residue 120; (4) a four-base deletion (1 176delGAAG) of genomic nt gl 1154-11158 that resulted in a frameshift in codon 392, the incorporation of one different amino acid (Thr) and premature termination after codon 394; and (5) a single-base deletion (1188delC) of genomic nt gill 66 that caused a frameshift in codon 396 with the incorporation of an abnormal sequence of seven amino acids (residues 396-403) and premature termination after residue 403.
Discussion
Analysis of the a-Gal A gene in 30 unrelated probands with Fabry disease identified 20 new mutations and 9 previously reported lesions. Se- 
Het, heterozygote.
acDNA reference sequence (10).
bGenomic reference sequence (2).
'Classic or cardiac phenotype. (14) . Notably, none of the new missense or nonsense mutations occurred at the 14 CpG dinucleotides of the a-Gal A coding sequence, and each was a "private" mutation that occurred in a single family. Among the 10 families with the 9 previously reported mutations, there were 5 missense and 3 nonsense mutations. Of these, only R1 12C and R227X occurred at CpG dinucleotides. Haplotype analysis of the a-Gal A flanking region in the two families with the common non-CpG N215S lesion revealed different alleles at three of the seven polymorphisms flanking the a-Gal A gene ( Fig. 1 and Table 2 ). The fact that two of three of these informative markers were close to the a-Gal A gene (<100 kb) suggested that these patients were not related.
Three acceptor consensus splice site (IVS61). These intronic mutations in the 5' donor and 3' acceptor consensus sequences are known to cause aberrant splicing (8) .
Of the gene rearrangements, the 35de11 3 mutation involved the deletion of a GC-rich sequence GCGCGCTTGCGCT, which contained five GC repeats. Both breakpoints were immediately flanked by the trinucleotide short repeats GCT and its inverse TCG, which suggested that illegitimate recombination or a slipped mispairing event may have been the deletional mechanism. In addition, two small deletions were detected within a 13-base pair region in exon 7 (11 76del4 and 1181 dell). The identification of these deletions further supports the previous suggestion that exon 7 is a region prone to small gene rearrangements (7) .
All of the novel mutations were identified in classically affected probands or in obligate heterozygotes whose affected sons had the classic phenotype with the exception of P259L. This missense mutation was identified in a 38-year-old cardiac variant with left heart enlargement and minimal proteinuria. In addition, the two patients with the previously identified N2 15S mutation also had the cardiac variant phenotype.
In summary, the identification of these 20 new mutations further documents the remarkable genetic heterogeneity of the a-Gal A lesions causing Fabry disease. Mutation analysis is important for each Fabry family, as the detection of these mutations permits precise diagnosis of heterozygous carriers of this X-linked recessive gene and provides the ability to perform molecular prenatal diagnoses. In addition, the detection of these mutations is useful for evaluation of genotype-phenotype correlations as well as for insights into the enzyme's structure-function relationships.
